Malaria Vaccine Testing Facility Operation

IDIQ

Description

The mission of the Laboratory of Malaria Immunology and Vaccinology (LMIV) is to develop malaria vaccines. The LMIV requires the assistance of contractors that can conduct Clinical trials to investigate initial safety, immunogenicity, and biologic impact of promising LMIV developed vaccine candidates. LMIV may also require that selected contractors conduct clinical studies of pathogenesis research to facilitate vaccine development.

Overview

Ceiling

$24,426,295

Primary Sponsoring Agency

Division of Extramural Activities (DEA) [HHS - NIH]

Who Can Use

One Agency

Primary NAICS

541711 - Research And Development In Biotechnology

Primary PSC

AN11 - Health R&D Services; Health Care Services; Basic Research

Primary Set Aside

None

Extent Competed

Full And Open Competition

Malaria Vaccine Testing Facility Operation awarded by Division of Extramural Activities (DEA) in November 2015 accepts orders through November 2020. The IDIQ has a reported ceiling of $24,426,295, and as of today, $51,273 has been obligated through the vehicle. The IDIQ was awarded full & open and has a primary NAICS code of 541711.

Award Hierarchy

Vehicle

Malaria Vaccine Testing Facility Operation

Indefinite Delivery Vehicles

Prime Contracts

Subcontracts

Status

Period of Performance

11/2/15

Start Date

11/1/20

Ordering Period End Date

100% Complete

Task Order Obligations

$51.3K

Total Obligated

$51.3K

Current Award

$51.3K

Potential Award

100% Funded

Vehicle Award Share

Contractors with greatest percentage of obligations for Malaria Vaccine Testing Facility Operation

Vehicle Award Share

Federal Award Analysis